These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8210256)

  • 21. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
    Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group].
    Negoro S; Fukuoka M; Niitani H; Suzuki A; Nakabayashi T; Kimura M; Motomiya M; Kurita Y; Hasegawa K; Kuriyama T
    Gan To Kagaku Ryoho; 1991 May; 18(6):1013-9. PubMed ID: 1851408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful treatment of chemotherapy-resistant adult T cell leukemia/lymphoma by irinotecan hydrochloride (CPT-11)].
    Makino T; Nakahara K; Takatsuka Y; Shimotakahara S; Utsunomiya A; Hanada S; Tokunaga M; Arima T
    Rinsho Ketsueki; 1994 Jan; 35(1):42-8. PubMed ID: 8139101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [EPOCH therapy for relapsed/refractory lymphoid malignancies].
    Dobashi N; Usui N; Kobayashi T; Yamazaki H; Asai O; Yano S; Kato A; Watanabe H; Nagamine M; Katori M; Tajima N; Kuraishi Y
    Rinsho Ketsueki; 1998 Apr; 39(4):267-72. PubMed ID: 9597893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
    Fukuoka M; Niitani H; Suzuki A; Motomiya M; Hasegawa K; Nishiwaki Y; Kuriyama T; Ariyoshi Y; Negoro S; Masuda N
    J Clin Oncol; 1992 Jan; 10(1):16-20. PubMed ID: 1309380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New antitumor drugs for malignant lymphoma: a review].
    Ohnishi K; Ohno R
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1157-62. PubMed ID: 8031156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Takamizawa H; Takeda Y; Ohkawa T; Tamaya T; Noda K; Sugawa T; Sekiba K; Yakushiji M; Taguchi T
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):579-84. PubMed ID: 2012400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
    Nishimura G; Satou T; Yoshimitsu Y; Kurosaka Y; Fujimura T; Sugiyama K; Kanno M; Yonemura Y; Miwa K; Miyazaki I
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):93-7. PubMed ID: 7826085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
    Armand JP; Extra YM; Catimel G; Abigerges D; Marty M; Clavel M
    Ann Oncol; 1996 Oct; 7(8):837-42. PubMed ID: 8922198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
    Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
    Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
    Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
    Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
    Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
    Ann Oncol; 1999 May; 10(5):577-83. PubMed ID: 10416008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.
    Ohno R; Kimura K; Amaki I; Hirano M; Hoshino A; Ikeda Y; Kimura I; Kobayashi M; Konno K; Majima H
    Cancer Chemother Pharmacol; 1987; 20(3):230-4. PubMed ID: 3315282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
    Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.